logo
Is Africa splitting in two? Scientists uncover fiery force tearing the continent apart faster than predicted

Is Africa splitting in two? Scientists uncover fiery force tearing the continent apart faster than predicted

Economic Times23-05-2025

iStock Scientists have uncovered a massive superheated force beneath East Africa that's rapidly tearing the continent apart. The East African Rift, once thought to take tens of millions of years to split, may now form a new ocean in just one to five million years.
Deep beneath the sun-scorched plains of East Africa, something extraordinary is unfolding—something so vast in scale that it could eventually reshape the very face of our planet. A new study has revealed that the East African Rift System (EARS), the 2,000-mile-long tear that runs from Ethiopia to Malawi, is ripping apart the continent at nearly double the previously estimated speed.
According to a report from the Daily Mail , this dramatic process, long thought to be glacially slow, is being accelerated by a powerful and ancient force surging from the depths of the Earth—a massive upwelling of superheated rock known as the African Superplume. Scientists say this 'giant hot blob' is not only pushing tectonic plates apart but also elevating the continent by hundreds of meters. And its influence is far greater—and faster—than once believed.
At the heart of this seismic drama lies the boundary between the Somali Plate and the Nubian Plate, where GPS tracking has long recorded their gradual separation. But new research led by scientists from the University of Glasgow, using advanced isotope tracing and high-precision mass spectrometry, now suggests that this process is being driven from deep within the Earth's mantle—far deeper than surface tectonic activity alone could explain.
By studying the isotopes of the noble gas neon from Kenya's Menengai geothermal field, researchers traced the chemical signature back to the core-mantle boundary. It's a smoking gun that confirms the presence of the African Superplume—an enormous reservoir of molten rock fueling the continental rift. "We've always known the surface was changing, but now we know the true power lies far below," said lead author Professor Fin Stuart. "This upwelling force is not only driving the plates apart, it's lifting the entire region."
The consequences of this tectonic ballet are already visible on the surface. In 2005, a sudden swarm of over 400 earthquakes in Ethiopia's Afar region opened a staggering 37-mile-long fissure in just days. In 2018, another colossal crack tore through Kenya's Great Rift Valley, halting traffic and making headlines around the world. As the rift continues to widen—now at around 0.2 inches per year—the stage is being set for an entirely new ocean to form. According to marine geophysicist Ken Macdonald, 'The Gulf of Aden and the Red Sea will eventually flood into the East African Rift Valley. A new ocean will be born.' In the distant future—possibly within just one to five million years—countries like Somalia, eastern Ethiopia, Kenya, and Tanzania could drift away from the mainland, creating a new continent altogether. Meanwhile, landlocked nations such as Uganda and Zambia might find themselves with coastlines, completely reshaping regional geopolitics and trade routes.
— Rainmaker1973 (@Rainmaker1973)
Beyond the astonishing visuals and dramatic forecasts, this research underscores a profound truth: our planet is in constant, powerful motion. What appears to be solid and eternal underfoot is, in reality, shifting, cracking, and transforming.
The East African Rift is not just a tear in the Earth's crust—it's a preview of planetary rebirth, a glimpse into the same elemental forces that once shaped the Atlantic Ocean and will eventually redraw the map once again. So, are the continents breaking apart faster than we imagined? The science says yes—and East Africa is just the beginning.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

COVID-19 resurgence: New variant found in China is just 'small mutation' away from causing a pandemic again, warn scientists
COVID-19 resurgence: New variant found in China is just 'small mutation' away from causing a pandemic again, warn scientists

Time of India

time2 days ago

  • Time of India

COVID-19 resurgence: New variant found in China is just 'small mutation' away from causing a pandemic again, warn scientists

Amid the fresh spike in COVID-19 cases across Southeast Asian countries, including Singapore, Thailand, Hong Kong, and India, American researchers suspect that a new COVID-19 variant called HKU5-CoV-2, discovered in China, could lead to another pandemic. Scientists have warned that the new HKU5-CoV-2 virus is just a 'small mutation' away from becoming a highly infectious variant. This is suspected to cause an outbreak among human beings. According to the Daily Mail, the pathogen detected in the virus is closely linked to MERS, which is considered to be a lethal virus that can kill up to a third of its affected population. What is the HKU5 variant of COVID-19? During the research conducted in 2020 during the COVID-19 pandemic, the HKU5 variant was found in bats in a Chinese lab. A study from Washington State University recorded the unique pathogens interacting with human cells. The co-leader of the study, Professor Michael Letko, confirmed that the viruses are infectious among human cells. The study further revealed that a small change in the virus HKU5's spike protein can potentially blind the ACE2 cells in the human body. 🚨 BREAKING: A new, dangerous coronavirus strain, HKU5-CoV-2, found in Chinese bats could spark the next pandemic, scientists warn. It uses the same human cell entry as COVID-19. Are we prepared for another global health crisis? #Coronavirus #GlobalHealth #PandemicThreat This virus is commonly found in the throats, mouths, and noses, which act as receptors for coronavirus. How lethal is the HKU5-CoV-2 strain of COVID-19? The results of the study noted that the HKU5-CoV-2 strain only spreads in bats; however, the scientists fear that this can be a major cause of concern for further lethal spread. As per the scientists, the 'pseudo-viruses' were created with specific gene editing to test various types of cells and how they react to them. Not only this, but some bats carrying ACE2 were also tested along with this. It also showed little response in human cells unless the virus carried specific mutations. However, the major concern is raised by the possibility of the HKU5 variant reaching an intermediate animal stage. Humid conditions are the breeding ground for HKU5 variants According to the findings, the virus is susceptible to wetness and humidity, which are the breeding grounds for the mutation of the HKU5-CoV-2 virus, which serves as an international host of transmission from animals to human beings. However, the resemblance to the highly contagious Middle East Respiratory Syndrome (MERS) is the main source of concern for the scientists. Although some variants did attach to human ACE2 cells, researchers are still examining the mutation pattern and its likelihood of infecting human beings. Symptoms of HKU5-CoV-2 There are no confirmed cases of HKU5-CoV-2 variants in human beings so far; hence, its symptoms are unknown, but since the virus belongs to the same subgenus as MERS and COVID-19, it may cause similar respiratory symptoms: Fever Cough Shortness of breath Sore throat Fatigue Body aches

A common drug shows promise for patients with liver disease
A common drug shows promise for patients with liver disease

Time of India

time2 days ago

  • Time of India

A common drug shows promise for patients with liver disease

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in treating severe liver conditions like MASH and liver fibrosis. The study, involving 154 participants, demonstrated significant improvements in MASH and fibrosis among those receiving dapagliflozin compared to the placebo group, suggesting a potential new treatment avenue. Liver disease accounts for two million deaths annually. This is 4% of all deaths (1 out of every 25 deaths worldwide), as per the data from 2023. Liver disease is a growing global health concern. A new study suggests that a widely used diabetes medication may offer hope for patients suffering from progressive liver disease. A recent clinical trial conducted in China and published in The BMJ suggests that the type 2 diabetes drug dapagliflozin can help patients with severe liver conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, which have limited treatment options. What does the diabetes drug do (Pic courtesy: iStock) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, which is widely used to treat type 2 diabetes, has been shown to improve progressive liver disease. The Chinese researchers found that the drug improved metabolic dysfunction-associated steatohepatitis (MASH), a condition where excess fat accumulates in the liver, leading to inflammation and liver fibrosis (a buildup of scar tissue). MASH affects more than 5% of adults, and it is also common (30%) in people with diabetes or obesity. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo This can progress to cirrhosis in up to 25% of individuals. Though previous studies have suggested that SGLT-2 inhibitors can improve liver fat content, liver enzymes, and liver stiffness, no trial has been carried out in patients with MASH. The study To understand the effects of dapagliflozin in patients with MASH, the researchers conducted a study. The 48-week study had 154 participants, who were diagnosed with MASH following liver biopsies at six Chinese medical centers from November 2018 to March 2023. Participants had an average age of 35, and 85% were men. Nearly half (45%0 had type 2 diabetes, and most had evidence of liver fibrosis at various stages (33% stage 1, 45% stage 2, 19% stage 3). Following an initial screening biopsy, the participants were randomly assigned to receive 10 mg of dapagliflozin or a matching placebo once daily for 48 weeks. They attended health education sessions twice a year. The researchers also recorded body weight, blood pressure, blood glucose, liver enzymes, physical activity, diet, insulin, and lipids of the participants throughout the trial. MASH improvement was defined as a decrease of at least 2 points in non-alcoholic fatty liver disease activity score (NAS) or a NAS of 3 points or less. By the end of the study, which is after 48 weeks, the researchers observed that 53% (41 of 78) participants in the dapagliflozin group showed improvement in MASH without worsening of fibrosis (defined as no increase in fibrosis stage) compared with 30% (23 of 76) in the placebo group. 23% (18 of 78) participants in the dapagliflozin group showed resolution of MASH without worsening of fibrosis, compared with 8% (6 of 76) in the placebo group. Trump Health Scare: 'Cognitive Decline' Spotted? Political Adviser's BIG Warning Amid Dementia Claim They also saw improvement in fibrosis without worsening of MASH in 45% (35 of 78) participants in the dapagliflozin group compared with 20% (15 of 76) in the placebo group. 1% (1 of 78) in the dapagliflozin group and 3% (2 of 76) in the placebo group discontinued the treatment because of adverse events. What are the experts saying Fatty liver 'Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis,' they said. They added that large-scale and long-term trials are needed to further confirm these effects. The trial was conducted in a Chinese population, which limits its broader generalisability. They also noted that with the emergence of more drugs, therapeutic decisions will likely become increasingly tailored to individual patient profiles, they write. 'Ideally, such treatments should provide cardiovascular benefit, have an established safety profile, and be accessible to broad and diverse patient populations,' they concluded. One step to a healthier you—join Times Health+ Yoga and feel the change

This Cheap Tablet May Help Prevent Heart Failure, Says Study
This Cheap Tablet May Help Prevent Heart Failure, Says Study

News18

time3 days ago

  • News18

This Cheap Tablet May Help Prevent Heart Failure, Says Study

Last Updated: Researchers found the drug reduced heart stiffness caused by diabetes, which weakens energy conversion in the heart and raises the risk of sudden heart failure A new study has revealed that an inexpensive medication can significantly reduce the risk of heart failure or heart attack in diabetes patients. According to the study, diabetes patients who took the affordable drug Mitoquinone had a much lower risk of heart attack compared to those who did not take the medication. Priced at just 90 pence in Britain, Mitoquinone is available as an over-the-counter supplement in both the UK and the US. According to a Daily Mail report, the most remarkable finding of the study was that heart damage in diabetic patients was also reversed after being given the drug mitoquinone. This is significant, as heart muscles typically weaken in diabetic patients. Mitoquinone is a synthetic antioxidant that protects cells and is a modified form of CoQ10, an antioxidant naturally found in the body. Study author and heart specialist at the University of Leeds, Dr. Henry Proctor, called the results encouraging. He added that if the study had been conducted over a longer period, the difference between the mitoquinone and non-mitoquinone groups might have been more apparent in serious indicators of heart health. However, he expressed hope that larger studies will continue on the benefits of this antioxidant, which could one day help diabetic patients prevent heart failure in advance. Heart Function Rises 15% With New Drug The results of the study were presented at the British Cardiovascular Society conference in Manchester. Half of the patients included in the study were given 40 mg of mitoquinone daily along with their usual diabetes treatment, while the rest were given only their usual medicines. The heart health of both groups was studied and re-evaluated after four months. At the end of the trial, the heart function of the group taking mitoquinone was found to be 15 percent higher than at the beginning of the study. The mitoquinone group also showed improvement in exercise tests. Their hearts returned to a relaxed state more easily after exercise. Researchers said that after taking the medicine, the stress and stiffness in the heart caused by diabetes was reduced. Diabetes damages the heart in such a way that the heart becomes weak in converting energy. Over time, this obstacle increases the stress and damage to the heart muscle cells, due to which the heart muscles become stiff. In this condition, more effort is needed to pump blood throughout the body, which increases the risk of sudden heart failure. No Side Effects Reported Mitoquinone helps protect cells from damage. It is already sold online as a health supplement, with a 60-tablet bottle priced around £50—roughly 86 pence per tablet. However, these over-the-counter doses are much lower than those used in the study. Importantly, no side effects were reported in the group taking mitoquinone. Scientists are now planning a larger trial involving more patients to strengthen their findings. If future studies confirm these results, experts hope mitoquinone could one day be used to protect the hearts of diabetic patients for longer. First Published: June 04, 2025, 18:22 IST

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store